欧洲DRESS患者的管理与治疗结局:一项纳入141例病例的国际多中心回顾性研究
该研究回顾性纳入欧洲8个三级中心2016年1月至2020年12月间141例可能或确定DRESS(RegiSCAR评分≥4)患者,描述治疗方式并分析预后因素。73%使用全身糖皮质激素,25.5%仅外用糖皮质激素,总死亡率为7.1%。死亡独立预测因素包括年龄≥57.0岁、肾脏受累和入住重症监护病房。
要点
- 141例DRESS患者中,皮疹以麻疹样发疹最常见(78.0%),42%出现红皮病。
- 73%接受全身糖皮质激素治疗,25.5%仅外用糖皮质激素,总死亡率7.1%。
- 年龄≥57.0岁、肾脏受累和入住ICU与3个月死亡独立相关。
核心结论
- 研究强调需要诊断和预后评分/标志物,以及可能降低DRESS死亡率和并发症的药物前瞻性临床试验。
研究设计与样本
- 欧洲多中心回顾性研究,纳入2016年1月至2020年12月间8个三级中心的141例可能或确定DRESS(RegiSCAR评分≥4)患者。
主要发现
- 麻疹样发疹为最常见皮肤表现(78.0%),平均受累体表面积67%,42%出现红皮病,24.8%有黏膜受累。
- 31.9%患者为重度DRESS,最常见致病药物为抗惊厥药(24.1%)和磺胺类(22.0%)。
- 73%患者使用全身糖皮质激素,25.5%仅外用糖皮质激素,少数使用抗病毒药或抗IL-5,无患者使用静脉免疫球蛋白。
- 总死亡率为7.1%,死亡独立预测因素为年龄≥57.0岁(完全校正OR 9.80,95%CI 1.20-79.93,p=0.033)、肾脏受累(完全校正OR 4.70,95%CI 1.00-24.12,p=0.049)和入住ICU(完全校正OR 8.12,95%CI 1.90-34.67,p=0.005)。
- DRESS复发和迟发性自身免疫后遗症分别发生于8.5%和12.1%的患者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but potentially fatal drug hypersensitivity reaction. OBJECTIVE: To explore treatment approaches across Europe and their impact on the disease course, as well as prognostic factors and culprit drugs. METHODS: In this retrospective European multicentric study, we included patients with probable or certain DRESS (RegiSCAR score ≥ 4) between January 2016 and December 2020. Independent associations between clinical parameters and the risk of intensive care unit admission and mortality at three months were assessed using a multivariable-adjusted logistic regression model. RESULTS: A total of 141 patients from 8 tertiary centres were included. Morbilliform exanthem was the most frequent cutaneous manifestation (78.0%). The mean affected body surface area (BSA) was 67%, 42% of the patients presented with erythroderma, and 24.8% had mucosal involvement. Based on systemic involvement, 31.9% of the patients had a severe DRESS. Anticonvulsants (24.1%) and sulphonamides (22.0%) were the most frequent causative agents. In all, 73% of the patients were treated with systemic glucocorticoids, and 25.5% received topical corticosteroids as monotherapy. Few patients received antiviral drugs or anti-IL5. No patients received intravenous immunoglobulins. The overall mortality was 7.1%. Independent predictors of mortality were older age (≥57.0 years; fully adjusted OR, 9.80; 95% CI, 1.20-79.93; p = 0.033), kidney involvement (fully adjusted OR, 4.70; 95% CI, 1.00-24.12; p = 0.049), and admission in intensive care unit (fully adjusted OR, 8.12; 95% CI, 1.90-34.67; p = 0.005). Relapse of DRESS and delayed autoimmune sequelae occurred in 8.5% and 12.1% of patients, respectively. CONCLUSIONS: This study underlines the need for diagnostic and prognostic scores/markers as well as for prospective clinical trials of drugs with the potential to reduce mortality and complications of DRESS.
引用
- Kridin K, Brüggen MC, Walsh S, et al. Management and treatment outcome of DRESS patients in Europe: An international multicentre retrospective study of 141 cases. J Eur Acad Dermatol Venereol. 2022. PMID: 36479739. doi:10.1111/jdv.18808
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。